1832 Asset Management

1832 Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

1832 Asset Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-9	Closed	-$3.11K	–	896
2024 Q1	$3.11K	Buy	+9	New	+$2.96K	﹤0.01%	830
2023 Q2	–	Sell	-11,204	Closed	-$5.37M	–	853
2023 Q1	$5.37M	Buy	+11,204	New	+$5.24M	0.01%	400
2022 Q2	–	Sell	-3,081	Closed	-$1.71M	–	866
2022 Q1	$1.71M	Buy	+3,081	New	+$1.86M	﹤0.01%	571
2017 Q1	–	Sell	-7,500	Closed	-$1.2M	–	703
2016 Q4	$1.2M	Hold	7,500	–	–	﹤0.01%	532
2016 Q3	$1.23M	Hold	7,500	–	–	﹤0.01%	440
2016 Q2	$1.08M	Buy	7,500 +3,500	+88%	+$499K	﹤0.01%	407
2016 Q1	$919K	Buy	+4,000	New	+$525K	﹤0.01%	415

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VanEck Associates

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Select Equity Group

Select Equity Group New York $18.8B AUM 17.33% 1-Year Est. Return

First Eagle Investment Management

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

EARNEST Partners

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Invesco Atlanta, Georgia $653B AUM 32.41% 1-Year Est. Return

Dimensional Fund Advisors

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return